3/14/2024 | BKHYIG | Fitch downgrades Bayer
|
3/11/2024 | BKHYIG | S&P revises Bayer outlook to stable
|
11/24/2023 | BKHYIG | Moody’s revises Bayer view to negative
|
9/21/2023 | EULM | Bayer sets tender cap for 2074 notes, 2079 notes at €1.75 billion
|
9/21/2023 | BKHYIG | S&P assigns BB+ to Bayer notes
|
9/20/2023 | HY | New Issue: Bayer prices €1.75 billion of subordinated notes in two parts
|
9/19/2023 | EULM | Bayer starts tender offer for subordinated notes due 2074, 2079
|
9/19/2023 | HY | Bayer explores issuing dual-tranche offering of split-rated hybrids
|
8/31/2023 | BKHYIG | Fitch revises Bayer outlook to negative
|
5/16/2023 | BKHYIG | Moody's stabilizes outlook on Bayer
|
5/15/2023 | BKCVHYIG | S&P revises Bayer outlook to positive
|
4/4/2022 | EULM | Bayer accepts €1.04 billion in tender offer for 2.375% resettable notes
|
3/30/2022 | EULM | Bayer extends capped tender offer for 2.375% resettable notes due 2075
|
3/22/2022 | EULM | Bayer begins capped tender offer for 2.375% resettable notes due 2075
|
3/22/2022 | BKHYIG | Moody's assigns Ba1 to Bayer notes
|
3/22/2022 | BKHYIG | S&P rates Bayer hybrids BB+
|
12/8/2021 | BKCVHYIG | Moody's changes Bayer view to negative
|
5/28/2021 | BKCVIG | Moody's downgrades Bayer
|
10/5/2020 | BKCVIG | Moody’s alters Bayer view to negative
|
6/29/2020 | BKCVIG | Fitch revises Bayer view to stable
|
6/29/2020 | BKCVIG | Moody’s changes Bayer view to stable
|
11/7/2019 | BKCVIG | Fitch gives Bayer hybrids BBB-
|
11/7/2019 | BKCVIG | S&P rates Bayer hybrids BB+
|
11/7/2019 | BKCVIG | Moody’s gives Bayer hybrids Baa3
|
7/8/2019 | BKCVIG | Fitch cuts Bayer
|
12/31/2018 | IG | Outlook 2019: Continued softness in high-grade bond spreads eyed for market in 2019
|
12/11/2018 | EMHYPFPV | Market Commentary: High-grade issuance quiet; Eversource Energy tightens; Bayer, Dow Chemical notes soften
|
12/11/2018 | IG | Market Commentary: High-grade issuance quiet; Eversource Energy tightens; Bayer, Dow Chemical notes soften
|
7/13/2018 | EMHYPFPV | Market Commentary: Primary quiet; high-grade inflows improve; Charter Communications tightens; Bayer mixed
|
7/13/2018 | IG | Market Commentary: Primary quiet; high-grade inflows improve; Charter Communications tightens; Bayer mixed
|
7/12/2018 | EMHYPFPV | Market Commentary: Sumitomo Mitsui prices $2 billion; Nordic Investment sells notes; Charter, Bayer strong
|
7/12/2018 | IG | Market Commentary: Sumitomo Mitsui prices $2 billion; Nordic Investment sells notes; Charter, Bayer strong
|
7/6/2018 | EMHYPFPV | Market Commentary: High-grade primary market quiet, supply forecast; Charter remains tight; credit spreads firm
|
7/6/2018 | IG | Market Commentary: High-grade primary market quiet, supply forecast; Charter remains tight; credit spreads firm
|
7/3/2018 | EMHYPFPV | Market Commentary: High-grade issuers quiet ahead of holiday; Walmart, Charter flat; Bayer, CVS Health soften
|
7/3/2018 | IG | Market Commentary: High-grade issuers quiet ahead of holiday; Walmart, Charter flat; Bayer, CVS Health soften
|
7/2/2018 | EMHYPFPV | Market Commentary: Investment-grade primary market quiets ahead of holiday; Charter, Bayer notes tighten
|
7/2/2018 | IG | Market Commentary: Investment-grade primary market quiets ahead of holiday; Charter, Bayer notes tighten
|
6/27/2018 | EMHYPFPV | Market Commentary: Supply thins; Principal Life, Municipality Finance price; Quebec on deck; Bayer tightens
|
6/27/2018 | IG | Market Commentary: Supply thins; Principal Life, Municipality Finance price; Quebec on deck; Bayer tightens
|
6/26/2018 | EMHYPFPV | Market Commentary: Freeport, Penske, USAA Capital price; Toyota holds calls; Municipality Finance on deck
|
6/26/2018 | IG | Market Commentary: Freeport, Penske, USAA Capital price; Toyota holds calls; Municipality Finance offers notes
|
6/25/2018 | EMHYPFPV | Market Commentary: World Bank prices $500 million floaters; corporates quiet; Walmart notes firm; Bayer eases
|
6/25/2018 | IG | Market Commentary: World Bank prices $500 million floaters; corporates quiet; Walmart notes firm; Bayer eases
|
6/25/2018 | IG | Market Commentary: Morning Commentary: Investment-grade primary market quiet; light supply for week forecast
|
6/22/2018 | IG | Market Commentary: Lighter volume forecast in week ahead; new issues trade mostly wider; Bayer, Walmart mixed
|
6/22/2018 | EMHYPFPV | Market Commentary: Lighter volume forecast in week ahead; new issues trade mostly wider; Bayer, Walmart mixed
|
6/22/2018 | IG | Market Commentary: Morning commentary: Fannie Mae sells notes; market activity quiet; high-grade inflows decline
|
6/21/2018 | EMHYPFPV | Market Commentary: AT&T, Protective Life, Con Ed, Alabama Power price bonds; Walmart mixed; Bayer softens
|
6/21/2018 | IG | Market Commentary: AT&T, Protective Life, Con Edison, Alabama Power price bonds; Walmart mixed; Bayer softens
|
6/21/2018 | IG | Market Commentary: Morning Commentary: Consolidated Edison offers debentures; lighter supply into July forecast
|
6/20/2018 | EMHYPFPV | Market Commentary: Walmart sells $16 billion notes; supply heavy; RBS, EQT, Marvell, UBS, BofA print bonds
|
6/20/2018 | IG | Market Commentary: Walmart sells $16 billion notes; supply heavy; RBS, EQT, Marvell, UBS, BofA print bonds
|
6/20/2018 | IG | Market Commentary: Morning Commentary: Walmart offers nine tranches; EQT Midstream, RBS, Xcel, Finnvera on deck
|
6/19/2018 | EMHYPFPV | Market Commentary: Oneok sells $1.25 billion; primary thin; Finnvera to offer notes; market eyes Walmart
|
6/19/2018 | IG | Market Commentary: Oneok sells $1.25 billion; primary thin; Finnvera to offer notes; market eyes Walmart
|
6/19/2018 | IG | Market Commentary: Morning Commentary: Oneok plans bond offering; market eyes Walmart deal; May inflows decline
|
6/18/2018 | EMHYPFPV | Market Commentary: Bayer prices $15 billion; Duke Energy Florida sells $1 billion; Walmart deal in focus
|
6/18/2018 | IG | Market Commentary: Bayer prices $15 billion; Duke Energy Florida sells $1 billion; Walmart deal in focus
|
6/18/2018 | IG | New Issue: Bayer prices $15 billion of senior notes in eight tranches
|
6/18/2018 | IG | Market Commentary: Morning Commentary: Duke Energy lines up deal; strong supply eyed; Walmart holds calls
|
6/15/2018 | EMHYPFPV | Market Commentary: Strong high-grade supply forecast; market eyes Bayer deal; Walmart considers offering
|
6/15/2018 | IG | Market Commentary: Strong high-grade supply forecast; market eyes Bayer deal; Walmart considers offering
|
6/13/2018 | EMHYPFPV | Market Commentary: High-grade volume quiet; Bayer, Digital Realty, Antares hold investor calls; AT&T flat
|
6/13/2018 | IG | Market Commentary: High-grade volume quiet; Bayer, Digital Realty, Antares hold investor calls; AT&T flat
|
6/13/2018 | IG | Market Commentary: Morning Commentary: Supply quiets on Fed meeting; Bayer, Digital Realty start investor calls
|
6/12/2018 | EMHYPFPV | Market Commentary: HSBC, Sanofi, Alexandria Real Estate, Kommuninvest price; AT&T firms on deal approval
|
6/12/2018 | IG | Market Commentary: HSBC, Sanofi, Alexandria Real Estate, Kommuninvest price; AT&T firms on deal approval
|
6/12/2018 | CVIG | Fitch gives A- to Bayer units’ debt
|
6/12/2018 | IG | Market Commentary: Morning Commentary: Sanofi, Alexandria Real Estate offer notes; Kommuninvest on tap
|
6/11/2018 | EMHYPFPV | Market Commentary: JPMorgan, Prologis, Air Lease, E*Trade price; Kommuninvest plans deal; Bayer in pipeline
|
6/11/2018 | IG | Market Commentary: JPMorgan, Prologis, Air Lease, E*Trade price; Kommuninvest plans deal; Bayer in pipeline
|
6/11/2018 | IG | Bayer to hold investor calls for possible dollar notes to fund Monsanto merger
|
6/8/2018 | IG | Market Commentary: Valmont prices add-ons to two tranches; lighter supply forecast; bonds mixed, new issues firm
|
6/8/2018 | EMHYPFPV | Market Commentary: Valmont prices add-ons to two tranches; lighter supply forecast; bonds mixed, new issues firm
|
6/5/2018 | BKCVIG | Fitch cuts Bayer, notes
|
6/4/2018 | CVIG | Moody’s lowers Bayer notes
|
6/4/2018 | CVIG | S&P downgrades Bayer
|
6/4/2018 | IG | Market Commentary: Morning Commentary: Session opens with strong supply; Kraft Heinz, energy issuers offer notes
|
6/9/2017 | CV | New Issue: Bayer sells €1 billion 0.05% bonds exchangeable for Covestro shares at 105.25% of par
|
11/18/2016 | CVIG | S&P rates Bayer convertibles BBB
|
11/16/2016 | CV | Market Commentary: Weatherford, AMD gain; Endologix drops sharply; Medicines up; PDL BioPharma deal on tap
|
11/16/2016 | CV | New Issue: Bayer sells €4 billion three-year mandatory convertible notes to yield 5.625%, up 20%
|
11/15/2016 | CV | Market Commentary: Peabody Energy, Chesapeake convertibles trade up outright; Priceline busy; Blucora firms
|
11/15/2016 | CV | Bayer to sell €4 billion three-year mandatory convertible notes to yield 5.125%-5.625%, up 20%-25%
|
10/4/2016 | IG | Fitch keeps Bayer on negative watch
|
9/14/2016 | EMHYPFPV | Market Commentary: 3M, Thermo Fisher, Aflac, Telus, Ventas Realty, PECO Energy price; Monsanto mostly flat
|
9/14/2016 | IG | Market Commentary: 3M, Thermo Fisher, Aflac, Telus, Ventas Realty, PECO Energy price bonds; Monsanto mostly flat
|
9/14/2016 | IG | Market Commentary: Morning Commentary: High-grade supply on tap; Royal Bank of Scotland eases; Libor yield rises
|
9/14/2016 | CV | Bayer plans mandatory convertible bonds for Monsanto acquisition
|
5/24/2016 | IG | Moody’s puts Bayer on downgrade review
|
5/24/2016 | IG | Fitch puts Bayer on watch
|
5/20/2016 | IG | S&P puts Bayer on watch
|
2/10/2016 | SP | RBC plans buffered return optimization notes linked to European stocks
|
7/21/2015 | IG | Fitch assigns Bayer hybrid BBB+
|
3/30/2015 | IG | Moody’s rates Bayer hybrid Baa2
|
10/1/2014 | IG | Market Commentary: Bayer sells megadeal for purchase of Merck unit; CBL, Ares price; spreads generally ease
|
10/1/2014 | IG | New Issue: Bayer prices $7 billion of senior notes in six tranches
|
8/13/2014 | IGPF | Fitch rates Bayer notes BBB+
|
6/24/2014 | IGPF | Moody's rates Bayer hybrids Baa2
|
6/24/2014 | IG | S&P assigns Bayer notes BBB
|
5/9/2014 | IG | S&P revises Bayer to stable
|
5/8/2014 | IG | Fitch revises Bayer to negative
|
5/8/2014 | IG | Moody's: Bayer view to positive
|
5/6/2014 | BKIG | Bayer plans to use bridge facility to finance acquisition of Merck consumer care business
|
4/12/2013 | IG | Moody's: Bayer view positive
|
5/12/2009 | CV | Fitch affirms Bayer
|
4/23/2009 | SS | Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
|
6/3/2008 | CV | Moody's ups Bayer outlook to stable
|
2/11/2008 | SS | Market Commentary: Yahoo! plays hard to get with Microsoft; Kellwood goes with the flow; time running out on HLTH-WebMD deal
|
2/12/2007 | SS | Market Commentary: Four Seasons, Hilton, Starwood slide; Southwest soars; Eddie Bauer off; WCI up; Onyx rockets
|
10/11/2006 | BT | S&P: Pharmaceutical sales growth spurs mergers
|
9/21/2006 | BT | Bayer: FDA committee endorses Trasylol in bypass surgery patients
|
7/24/2006 | BT | Nexavar approved by European Commission for the treatment of advanced kidney cancer
|
7/20/2006 | BT | Bayer, Onyx receive FDA fast-track designation for Nexavar for advanced melanoma treatment
|
7/19/2006 | BT | CuraGen to receive royalties on Bayer's licensing of BAY 76-7171 for diabetes management
|
7/17/2006 | BTCV | Moody's confirms Bayer debt, cuts Schering; outlook negative
|
7/11/2006 | BTCV | S&P cuts Bayer, Schering
|
7/6/2006 | BT | Bayer Diabetes Care acquires diabetes monitoring company Metrika
|
7/3/2006 | BT | Market Commentary: Encore cheered as it goes private on Blackstone buyout at a 36% premium; Siemens, Bayer up
|
6/27/2006 | BTCV | S&P: Bayer still on watch
|
6/22/2006 | BT | Gen-Probe, Bayer settle patent disputes
|
6/21/2006 | BT | Bayer HealthCare Diagnostics gets FDA approval for automated HIV test
|
6/14/2006 | BT | Bayer to buy Merck's 21.8% stake in Schering at €89, Bayer drops lawsuit
|
6/14/2006 | BT | Pfizer to use Bayer compound to develop potential obesity, diabetes treatments
|
6/13/2006 | BT | Bayer purchases 530,471 Schering shares in open market, privately negotiated trades
|
6/6/2006 | BT | Bayer: Blood test helps predict clinical outcome to trastuzumab-based therapy
|
5/24/2006 | BT | Bayer reports promising early clinical trial results for its BAY 79-4980 product for hemophilia
|
5/11/2006 | BTCV | S&P keeps Bayer on negative watch
|
5/3/2006 | BT | Bayer, Onyx finish enrollment in Nexavar phase 3 trials
|
4/28/2006 | BT | Bayer, Onyx: European medicinal committee gives Nexavar positive recommendation in kidney cancer
|
4/26/2006 | BT | Bayer, Onyx granted orphan drug status for liver cancer drug Nexavar
|
4/18/2006 | BT | Schering's executive, supervisory boards recommend acceptance of Bayer takeover offer
|
3/30/2006 | BT | Bayer, Onyx drug Nexavar approved in Switzerland to treat patients with kidney cancer
|
3/30/2006 | BTCV | Bayer Capital greenshoe exercised, raising mandatory convertibles to €2.3 billion
|
3/29/2006 | BTCV | New Issue: Bayer Capital €2 billion mandatory convertibles yield 6.625%, up 17%
|
3/24/2006 | BT | Bayer offers to acquire Schering for €86 a share in a deal worth €16.3 billion
|
3/24/2006 | BT | S&P: Bayer on watch
|
3/24/2006 | BT | Moody's may cut Bayer
|
3/1/2006 | BT | Bayer signs blood immunoassay licensing agreement with Signet Labs
|
2/27/2006 | BT | Nuvelo, Bayer begin second phase 3 trial of alfimeprase for catheter occlusion
|
2/16/2006 | BT | Bayer, Onyx begin phase 3 non-small cell lung cancer trial of Nexavar tablets
|
2/9/2006 | BT | Bayer says some regulatory authorities issue caution on Trasylol use
|
1/26/2006 | BT | Bayer disputes Trasylol clinical trial results published in New England Journal of Medicine
|
1/5/2006 | BT | Nuvelo to partner with Bayer on alfimeprase in deal worth up to $385 million
|
1/3/2006 | BT | Bayer HealthCare buys European marketing rights for telmisartan from GlaxoSmithKline
|
12/20/2005 | BT | Bayer, Onyx announce FDA approval of Nexavar tablets to treat kidney cancer
|
12/15/2005 | BT | Sontra, Bayer amend license for Sontra's continuous glucose monitor
|
12/8/2005 | BT | Bayer begins phase 3 study of Trasylol to reduce bleeding during spinal fusion surgery
|
11/30/2005 | BT | Bayer gets FDA approval to market Avelox for complicated intra-abdominal infections
|
11/28/2005 | BT | Bayer receives FDA approval for Kogenate FS with Bio-Set for hemophilia
|
11/3/2005 | BT | Bayer to spin off anti-infectives research with Santo Holding as new company's majority owner
|
10/26/2005 | BT | Bayer HealthCare and Ortho-McNeil agree to joint development of BAY 59-7939
|
10/21/2005 | BT | Bayer's Avelox approved for Japanese markets
|